| Symbol | CYCN |
|---|---|
| Name | CYCLERION THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 245 FIRST STREET,18TH FLOOR, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 857 327-8778 |
| Fax | — |
| — | |
| Website | https://www.cyclerion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001755237 |
| Description | Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. Additional info from NASDAQ: |
New Form 425 - Cyclerion Therapeutics, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001193125-26-330785 <b>Size:</b> 43 KB
Read moreNew Form EFFECT - Cyclerion Therapeutics, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 9999999995-26-002441 <b>Size:</b> 1 KB
Read moreHecht Peter M 🟡 adjusted position in 0 shares (1 derivative) of Cyclerion Therapeutics, Inc. (CYCN) Transaction Date: Jul 16, 2026 | Filing ID: 309048
Read moreNew Form SCHEDULE 13D/A - Cyclerion Therapeutics, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001193125-26-309245 <b>Size:</b> 8 KB
Read moreNew Form S-4/A - Cyclerion Therapeutics, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001193125-26-263731 <b>Size:</b> 23 MB
Read moreNew Form SCHEDULE 13G - Cyclerion Therapeutics, Inc. <b>Filed:</b> 2026-05-07 <b>AccNo:</b> 0000315066-26-001385 <b>Size:</b> 11 KB
Read moreSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
Read moreCYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Read moreShareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03892499 | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on th… | Phase1 | Healthy | Completed | 2019-05-03 | 2019-07-03 | ClinicalTrials.gov |
| NCT03818295 | A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat… | Phase1 | Healthy Volunteers | Completed | 2019-03-01 | 2019-04-24 | ClinicalTrials.gov |
| NCT03795519 | A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat … | Phase1 | Healthy Volunteers | Completed | 2019-01-17 | 2019-02-27 | ClinicalTrials.gov |
| NCT03499106 | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on th… | Phase1 | Healthy | Completed | 2018-04-12 | 2018-07-06 | ClinicalTrials.gov |
| NCT03285178 | A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylat… | Phase2 | Sickle Cell Disease | Completed | 2017-12-22 | 2020-07-22 | ClinicalTrials.gov |
| NCT03254485 | A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Hear… | Phase2 | Heart Failure With Preserved Ejection Fraction | Completed | 2017-11-07 | 2019-08-19 | ClinicalTrials.gov |
| NCT03217591 | A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in D… | Phase2 | Type 2 Diabetes Mellitus With Diabetic Nephropathy | Completed | 2017-08-01 | 2019-08-20 | ClinicalTrials.gov |
| NCT02931565 | Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients … | Phase2 | Achalasia | Terminated | 2017-04-06 | 2018-05-01 | ClinicalTrials.gov |
| NCT03091920 | Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients W… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2017-02-28 | 2017-08-03 | ClinicalTrials.gov |
| NCT02906579 | A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2016-09-01 | 2017-03-17 | ClinicalTrials.gov |
| NCT02792998 | A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy… | Phase1 | Healthy | Completed | 2016-05-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02616861 | Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy V… | Phase1 | Healthy | Completed | 2015-11-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02572349 | Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy V… | Phase1 | Healthy | Completed | 2015-10-01 | 2015-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| [14C]-olinciguat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03795519 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03499106 |
| IW-1973 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03499106 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02792998 |
| IW-1701 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02792998 |
| Matching Placebo Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02616861 |
| IW-1973 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02616861 |
| Matching Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02572349 |
| IW-1701 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02572349 |
| [14C]-praliciguat | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03818295 |
| Itraconazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03892499 |
| Olinciguat | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03892499 |
| IW-1973 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02906579 |
| Matching Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT02906579 |
| Placebo | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03091920 |
| IW-1973 | Other | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT03091920 |
| Matching Placebo | Other | Phase PHASE2 | Achalasia | TERMINATED | NCT02931565 |
| Olinciguat | Other | Phase PHASE2 | Achalasia | TERMINATED | NCT02931565 |
| Placebo Oral Tablet | Other | Phase PHASE2 | Heart Failure With Preserved Ejection Fraction | COMPLETED | NCT03254485 |
| IW-1973 | Other | Phase PHASE2 | Heart Failure With Preserved Ejection Fraction | COMPLETED | NCT03254485 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus With Diabetic Nephropathy | COMPLETED | NCT03217591 |
| IW-1973 | Other | Phase PHASE2 | Type 2 Diabetes Mellitus With Diabetic Nephropathy | COMPLETED | NCT03217591 |
| Placebo | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT03285178 |
| IW-1701 | Other | Phase PHASE2 | Sickle Cell Disease | COMPLETED | NCT03285178 |